Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2021 | Update on lenalidomide for MDS

Valeria Santini • 23 Sep 2021
MDS 2021
Myelodysplastic Syndromes Lenalidomide

Valeria Santini, MD, University of Florence, Florence, Italy, provides an update on the use of lenalidomide for the treatment of myelodysplastic syndromes (MDS), highlighting the drugs’ importance in the management of del(5q) MDS. Prof. Santini goes on to discuss whether we should use lenalidomide in patients with del(5q) that are not transfusion-dependent. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals